Natick, MA – According to filings with the U.S. Securities and Exchange Commission, Pillar Biosciences is raising $50,587,836.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gang Song played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pillar Biosciences
Making precision medicine the first option for every patient. Enabling access to accurate testing. Reducing time to treatment decisions. Affordable testing closer to home. Pillar Biosciences aims to “Make precision medicine the first option for every patient” by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today’s high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly.

To learn more about Pillar Biosciences, visit http://www.pillar-biosciences.com/

Contact:
Gang Song, Chief Executive Officer
508-655-3027
songg@pillar-biosciences.com
https://www.linkedin.com/in/gang-song-b37a009/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved